Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
NCT03196349 · Duke University · PHASE4 · terminated · last registry update 2019-12-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment” | – | Registry record, Duke University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VKORC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-01Results posted on the registry: Imperial College London, Warfarin (NCT00180674)
- 2020-10-29Results posted on the registry: Abbott Medical Devices, Warfarin + acetylsalicylic acid (ASA) therapy (NCT02836652)
- 2020-10-19Results posted on the registry: Ohio State University, Atorvastatin + Anticoagulation Therapy (NCT02331095)
- 2020-10-19Also stopped (terminated): Ohio State University, Atorvastatin + Anticoagulation Therapy (NCT02331095)
- 2020-09-29Phase 3 first posted: Damascus University, Rivaroxaban + Warfarin (NCT04569279)
- 2020-08-12Results posted on the registry: Mayo Clinic, Vascular Boot + Standard of Care (NCT03465735)
- 2020-08-12Also stopped (terminated): Mayo Clinic, Vascular Boot + Standard of Care (NCT03465735)
- 2020-07-01Results posted on the registry: Eli Lilly and Company, warfarin + enzastaurin (NCT01388335)
- 2020-06-30Also stopped (terminated): Electrophysiology Research Foundation, Edoxaban + Warfarin (NCT02561897)
- 2020-05-15Also stopped (terminated): Hospital Geral Roberto Santos, Rivaroxaban 15 mg + Warfarin (NCT03566303)
- 2020-04-14Results posted on the registry: Abbott Medical Devices, a drug against VKORC1 (NCT01118299)
- 2020-03-17Results posted on the registry: Baim Institute for Clinical Research, Interrupted apixaban + Uninterrupted apixaban (NCT02608099)
- 2020-02-26Phase 3 first posted: Population Health Research Institute, DOAC + VKA (NCT04284839)
- 2020-02-10Results posted on the registry: Electrophysiology Research Foundation, Edoxaban + Warfarin (NCT02561897)
- 2019-12-11Results posted on the registry: William S. Middleton Memorial Veterans Hospital, Warfarin (NCT02392104)
- 2019-11-25Results posted on the registry: University of Chicago, Warfarin (NCT00964353)
- 2019-11-08Also stopped (terminated): University of Louisville, fondaparinux + warfarin (NCT00673439)
- 2019-10-29Phase 3 first posted: Artivion Inc., Apixaban 5 MG + Apixaban 2.5 MG (NCT04142658)
- 2019-09-23Results posted on the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Edoxaban + VKA-Based Regimen (NCT02942576)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04067505)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04066764)
- 2019-08-21Also stopped (terminated): Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Sorafenib (NCT04051853)
- 2019-08-15Results posted on the registry: Boehringer Ingelheim, Dabigatran etexilate + Warfarin (NCT02913326)
- 2019-07-26Also stopped (terminated): Johannes Gutenberg University Mainz, Dabigatran etexilate + Phenprocoumon (NCT02256683)
- 2019-04-24Phase 3 first posted: Rajaie Cardiovascular Medical and Research Center, Rivaroxaban + Warfarin (NCT03926156)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision